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Abstract 
Background: In patients with cardiomyopathy of unknown origin, endomyocardial biopsy provides the possibility of 
improved diagnosis and tailored treatment. Specific guidance has been developed based on cardiovascular centre of 
excellence experience but it is unknown if the benefits also extend into the tertiary care hospital setting.
Methods: Endomyocardial biopsies was performed in patients with cardiomyopathy of unknown origin. The out‑
comes were mirrored against the current ESC recommendations.
Results: A total of 57 patients with cardiomyopathy of unknown origin underwent endomyocardial biopsy with a 
mean age of 54 years and 28 % being women. In 17 patients (30 %), viruses were detected in the biopsy material, in 
6 patients (11 %) cardiac amyloidosis was found of which 3 had also a positive test for viruses. The overall mortality 
rate was 18 % in the mean follow up period of 30 months, with a rate of 24 % in those with virus detection (mean FU 
24 months) and 15 % in those without virus detection (mean FU 31 months. Death rates were 83 % in patients with 
cardiac amyloidosis (mean FU 10 months).
Conclusion: We conclude that, limited by uncertainty stemming from the small number of included patients, endo‑
myocardial biopsy may not prove to have a clinical impact on treatment decisions and outcomes in a tertiary care 
hospital setting. We consider cardiac amyloidosis to be an exception, since the mortality rate with or without con‑
comitant virus load was extremely high.
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Background and objectives
In 31 % of patients with cardiomyopathy of unknown ori-
gin, clinical assessment of the cause is often inaccurate. 
However, a definitive diagnosis with high specificity can 
be reached for 75  % of these patients using endomyo-
cardial biopsy [1]. Involvement of the heart muscle in 
infectious-inflammatory or autoimmune disease can only 
be detected by examining myocardial biopsy samples. 
Specific myocardial disorders associated with individual 
prognoses and treatment options are rarely diagnosed 
through non-invasive tests [2]. Non-invasive imaging 
techniques, such as cardiac magnetic resonance imag-
ing (MRI), can identify aspects representative of certain 
causes. However, to confirm the diagnosis, endomyo-
cardial biopsy is essential [3]. When cardiac amyloidosis 
is suspected, endomyocardial biopsy is the gold stand-
ard for achieving an accurate diagnosis [4]. Amyloidosis 
patients with cardiac involvement have a poor prognosis. 
For them, an early and specific diagnosis is critical for 
allowing rapid introduction of modern therapy and an 
increase in treatment success [5].
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In a joint scientific statement from the American Heart 
Association (AHA), the American College of Cardiology 
(ACC), and the European Society of Cardiology (ESC) 
[6], the importance of endomyocardial biopsy in the 
treatment of cardiovascular diseases was clearly estab-
lished (Table  1). This recommendation was developed 
from data usually obtained in larger, highly specialized 
centres for the care of patients with cardiomyopathy. We 
were interested to see whether these recommendations 
as well as the specialized centre experience also applies to 
the situation in a tertiary care centre, with responsibility 
for a large variety of patients.
In the presently reported survey, endomyocardial biop-
sies were performed on patients with cardiomyopathy 
of unknown cause, and the outcomes compared with 
the aforementioned guidelines of the AHA, ACC, and 
ESC [6]. A special consideration was given to the ques-
tion whether we may find proof that these guidelines are 
applicable for clinical decision making and patient out-
comes in a tertiary care centre.
Study design and research methods
Between 2003 and 2013, a total of 14,775 diagnostic cor-
onary angiographies were performed in the cardiology 
centre of the Lippe Clinic, Detmold. From these, 1302 
patients (8.8  %) were diagnosed with cardiomyopathy. 
Based on their history, clinical course, and differential 
diagnosis and in accordance with the specific guidance 
[6] the decision for left ventricular myocardial biopsies 
(minimum 3–5 biopsies at different locations) was made 
in 57 patients (4.4 % of those with cardiomyopathy).
Patients were anonymized upon data entry and there-
fore ethical approval was not required [7, 8]. We obtained 
written informed consent for the procedure itself and 
specific consent from the patient described in the case 
report.
Histopathological and immunohistochemical analysis 
of endomyocardial biopsy samples
Examination of the samples was performed at the Insti-
tute of Molecular Pathology (Prof. Kandolf ) of the Uni-
versity of Tübingen. Sections of the tissue samples were 
stained with haematoxylin, eosin, Masson’s trichrome 
stain, and Giemsa. Immunohistochemical studies were 
also performed on tissue samples fixed with 4  % neu-
tral buffered formaldehyde solution [9]. Biopsy samples 
stained with Masson’s trichrome and haematoxylin-eosin 
(HE), and those embedded in paraffin, were examined 
by light microscopy. In the event of a diagnosis of car-
diac amyloidosis, samples would also be histologically 
stained with Congo red. The histological analysis was 
performed according to the Dallas criteria supplemented 
by immunohistochemistry for the evaluation of an ongo-
ing inflammatory reaction [10]. For immunohistochemi-
cal staining, tissues were treated with various antibodies 
conjugated to an avidin-biotin-peroxidase complex (Vec-
tastain-Elite, ABC Kit, Vector, Burlingame, CA, USA).
Molecular and virological analyses
Other biopsy samples were snap-frozen or fixed in RNAl-
ater (Ambion Inc., Foster City, CA, USA) for detection 
of the virus genome by polymerase chain reaction [PCR-
Nested-PCR/reverse transcription PCR (RT-PCR)]. This 
was carried out to detect the following viruses: Parvovi-
rus B19, human herpes virus type 6, enteroviruses (cox-
sackie and echo viruses), Epstein Barr virus, influenza 
virus A and B, adenovirus, herpes simplex virus, and 
varicella zoster virus [11]. Glyceraldehyde-3-phosphate 
dehydrogenase was used as an internal control to indicate 
successful isolation of nucleic acids. A biopsy was des-
ignated as positive if viral genetic material was detected 
by PCR. Specificity was ensured by automatic DNA 
sequencing of viral amplification products [12].











Women 16 (28 %) 7 (41 %) 9 (23 %) 1 (17 %) 15 (29 %)
Age (years) 54 49 55 73 51
Mean EF 50 % 51 % 50 % 64 % 49 %
EF <35 % 13 (23 %) 7 (41 %) 6 (15 %) 0 (0 %) 13 (26 %)
Virus‑positive 17 (30 %) 17 (100 %) 0 (0 %) 3 (50 %) 14 (28 %)
Amyloidosis‑positive 6 (11 %) 3 (18 %) 3 (8 %) 6 (100 %) 0 (0 %)
Death 10 (18 %) 4 (24 %) 6 (15 %) 5 (83 %) 5 (10 %)
Mean follow‑up (months) 30 28 31 10 33
Page 3 of 6Tebbe et al. BMC Res Notes  (2016) 9:459 
Statistics
For descriptive statistics, frequency (percentage) and 
mean values are reported. The probability of survival 
after myocardial biopsy is presented as a Kaplan Meier 
curve.
Results
Among the 57 patients documented (Table  1), the pro-
portion of women was 28  % and the mean age was 
54 years. A total of 17 patients were virus positive (30 %), 
6 were amyloid positive (11 %) and three were virus and 
amyloid positive (5  % of all, 50  % of those with cardiac 
amyloidosis).
Virus positive patients had an average age of 49 years 
with a fairly good ejection fraction (mean 51  %). None 
of them was receiving antiviral or immunosuppressive 
therapy. After a mean follow-up of 28  months 4 of the 
virus positive patients had died (24 %) which was nomi-
nally larger than in the virus negative group (6 patients or 
15 % after 31 months of follow-up). In Fig. 1, survival rate 
is divided into virus-positive and virus-negative patients 
without amyloidosis, and those with amyloidosis. The 
difference between the two groups without amyloidosis 
did not prove significant (p = 0.46).
Six patients were diagnosed with amyloidosis, with 
these being on average 22  years older than those with-
out (Table  1). Three of these also tested positive for 
virus genome. Again, none of the patients received anti-
viral or immunosuppressive therapy. While the EF was 
rather high in these patients (64  %), the prognosis was 
particularly poor with 83  % (5 out of 6 patients) dying 
within the first 10 months. This was substantially higher 
than the death rate in amyloid negative patients that was 
10  % after a mean follow-up of 33  months. The surviv-
ing virus-positive patient with transthyretin-related amy-
loidosis (ATTR) is currently undergoing treatment (see 
‘‘Case report’’ section).
Biopsy sampling was carried out safely and without 
complications. None of the 57 patients suffered cardiac 
tamponade or suffered from a neurological deficit.
Case report
A 71-year-old patient presented at a neurology clinic 
with increasing unsteadiness and numbness of the legs. 
He also complained of a sensation of pressure in the chest 
during exercise. Two years earlier, he had undergone an 
ambulatory coronary angiography in which a left bundle 
branch block and mildly impaired systolic function were 
observed, without evidence of stenotic heart disease. 
Owing to the presence of peripheral polyneuropathy, a 
biopsy was taken, and this tested positive for amyloido-
sis. A cardiac investigation was additionally performed 
because of the thoracic discomfort. Echocardiography 
revealed severe restrictive cardiomyopathy. Contrast-
enhanced cardiac MRI showed no evidence of intramyo-
cardial pathology attributable to amyloidosis. However, 
in a myocardial biopsy, amyloidosis was detected. Amy-
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Fig. 1 Long‑term prognosis after myocardial biopsy
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Genetic testing revealed a heterozygous status for muta-
tion c.233T > A (p.Lau78His) in the TTR gene. Thus, the 
diagnosis of systemic hereditary ATTR was reached. The 
patient was started on Tafamidis. Since the beginning of 
treatment (17 months so far), no disease progression has 
been observed.
Discussion
Limited by uncertainty stemming from the small num-
ber of included patients, endomyocardial biopsy may not 
prove to have a clinical impact on treatment decisions 
and outcomes in a tertiary care hospital setting. We con-
sider cardiac amyloidosis to be an exception, since the 
mortality rate with or without concomitant virus load 
was extremely high (83 % in 10 months).
Viral myocarditis
Viral myocarditis is an important causal factor in pro-
gression to dilated cardiomyopathy [13–16], currently 
the most common reason for heart transplantation [16]. 
Kindermann et  al. studied 181 patients with suspected 
viral myocarditis and came to the conclusion that a 
higher NYHA class, immunohistological inflammatory 
characteristics, and a lack of β-blocker therapy were 
associated with a poor prognosis, irrespective of histo-
logical criteria of myocarditis (Dallas criteria) or virus 
genome detection [17]. Schwab et al. indicated that early 
diagnosis of myocarditis is crucial, as positive patient 
outcomes can occur only when the myocardial regenera-
tive potential is still present. As the disease progresses, it 
may lead to irreversible myocardial injury, which would 
lead to development of heart failure and its progression 
[18]. There is one large study by Felker et  al. [2] show-
ing no difference in survival between cases of idiopathic 
and myocarditis based cardiomyopathy. They grouped 
patients into the categories idiopathic cardiomyopathy, 
peripartum cardiomyopathy and cardiomyopathy due 
to myocarditis, ischemic disease, infiltrative myocardial 
disease, hypertension, HIV- infection, connective tissue 
disease, substance abuse, therapy with doxorubicin and 
other causes. Felker et  al. conclude that the underlying 
cause of HF has prognostic value in patients with unex-
plained cardiomyopathy. Survival among the patients 
with cardiomyopathy due to myocarditis, substance 
abuse, hypertension, connective-tissue, disease, or 
other causes did not differ significantly from that among 
patients with idiopathic cardiomyopathy. The ESC 
Working Group on Myocardial and Pericardial Diseases 
reported that in up to 30 % of biopsy-proven myocardi-
tis, cardiomyopathy develops, resulting in poor progno-
sis [19]. Myocarditis covers a wide clinical spectrum and 
displays no pathognomonic symptoms [3]; therefore, it is 
often only detected at an advanced stage. Cooling et al. 
state in their review that such numerous and chronic 
viral infections and post-infectious autoimmune inflam-
mations of the myocardium are treatable and, therefore, 
early myocardial biopsy clarification is necessary in 
order to prevent the emergence of irreversible therapy-
refractory heart muscle damage [20]. To date, there is 
no evidence-based treatment recommendation, since 
the clinical trial situation is inadequate [3]. Immunosup-
pressive therapy appears to be effective in patients with 
virus-negative chronic myocarditis. However, this treat-
ment option, similar to immunomodulatory and antivi-
ral strategies, has yet to be investigated in randomised 
placebo-controlled trials [3].
Cardiac amyloidosis
In this study, it became clear that detection of cardiac amy-
loidosis was associated with a very poor prognosis. Only 
one of the 6 patients diagnosed with cardiac amyloidosis 
survived to receive adequate therapy. Cardiac involve-
ment usually manifests itself with nonspecific symptoms 
(decrease in performance, increase in exertional dyspnoea, 
peripheral oedema, palpitations, or syncope) [21]. For the 
diagnosis of cardiac amyloidosis, endomyocardial biopsy is 
the gold standard [4]. Through early and precise diagnosis, 
targeted therapy can be initiated. In our case study (patient 
with ATTR), this resulted in the successful start of therapy 
with the “orphan drug” Tafamidis.
Furthermore we had three out of six patients in which 
virus myocarditis was superimposed on a cardiac amyloi-
dosis. Although previously published [22], this is a rare 
observation. Lim et al published a similar case report in 
2006 where a 57  year-old women presented with acute 
myocarditis with a concomitant amyloidosis [22]. The 
patients showed arrhythmia due to a conduction dis-
order. The authors concluded that myocardial biopsies 
have proven helpful with regard to the diagnosis of acute 
myocarditis superimposed on amyloidosis, especially in 
patients which present conduction disorder and rather 
preserved ventricular function.
Limitations
This is a small case series of patients with diagnosed 
cardiomyopathy undergoing left ventricular myocar-
dial biopsy. Data were collected over a time-period of 
10 years in a tertiary care hospital. They are likely to be 
affected by bias in patient selection for biopsy and are 
subject to the bias clinical routine may impose in this set-
ting. They are not meant to challenge larger observations 
or trials, but they rather reflect clinical reality beyond 
large clinical centres specialising in cardiomyopathies. 
Further limitations include the lack of further data (such 
as immunospecific stain etc.) on the patients diagnosed 
with amyloidosis, the lack of a full documentation on the 
Page 5 of 6Tebbe et al. BMC Res Notes  (2016) 9:459 
indication for biopsy, the presence of active myocarditis, 
and on concomitant medication and treatment.
Conclusions
Patients with an indication for myocardial biopsy accord-
ing to the ESC Working Group on Myocardial and Peri-
cardial Diseases have an adequate long-term prognosis, 
with no difference between those having virus genome 
detected and those not. The observation is however lim-
ited by the small sample size a tertiary care centre is able 
to collect even in a 10 year frame. On the other hand the 
data illustrate the considerable impact of cardiac amyloi-
dosis on outcomes. Left ventricular myocardial biopsy 
was not associated with major complications affecting 
the decision to go for biopsy. We conclude that, lim-
ited by uncertainty stemming from the small number of 
included patients, endomyocardial biopsy may not prove 
to have a clinical impact on treatment decisions and out-
comes in a tertiary care hospital setting except for a clini-
cal suspicion of amyloidosis.
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